可吸收組織間隔器市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)
市場調查報告書
商品編碼
1272668

可吸收組織間隔器市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Absorbable Tissue Spacer Market - Growth, Trends, and Forecasts (2023 - 2028)

出版日期: | 出版商: Mordor Intelligence | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內,可吸收組織間隔器市場預計將以 4.9% 的複合年增長率增長。

COVID-19 大流行影響了世界各地的醫療保健系統,擾亂了許多醫療機構的正常護理,使易受傷害的癌症患者面臨重大風險。 據報導,由於易感性和免疫抑制,癌症患者患 COVID-19 並發症和死亡的風險增加。 因此,政府努力克服這些並發症。 例如,根據 SAGE Publications 發表的一篇文章,在 2021 年 12 月 COVID-19 大流行期間,社區衛生委員會將創建無 COVID-19 區以確保癌症治療的連續性安全。腫瘤中心。 歐洲腫瘤研究所 (IEO) IRCSS(意大利米蘭)就是其中之一。 因此,雖然 COVID-19 流行病在早期階段對市場增長產生了重大影響,但政府舉措後癌症治療的恢復對可吸收組織間隔器市場產生了重大影響。 此外,隨著 COVID-19 病例轉為下降,放療需求恢復正常水平,市場預計在預測期內將出現顯著增長。

推動市場增長的某些因素包括癌症患病率的增加以及與組織間隔物相關的益處。 受各種癌症影響的人數增加是市場增長的主要驅動力。 例如,根據美國癌症協會2023年1月公佈的數據,預計2023年美國將診斷出約1,958,310例新的癌症病例。 因此,預計癌症患病率的增加將對診斷和治療產生大量需求。 此外,根據澳大利亞政府 2023 年 1 月的更新,估計 2022 年將診斷出 20,640 例新的乳腺癌病例。 因此,人口中癌症的高負擔推動了對可吸收組織間隔器的需求,以提供足夠的保護並在放射治療期間形成強大的保護屏障,從而推動市場增長。

主要市場參與者採取的各種舉措(例如產品發布、擴張和合作夥伴關係)預計將在預測期內推動市場增長。 例如,2022 年 2 月,Palette Life Sciences 將 Palette 的醫療產品組合商業化。 我們正在擴大我們在日本的產品範圍,並積極尋求對 Barrigel 和 Solesta 品牌的監管批准。 預計此類新興市場的發展將在預測期內推動市場增長。

然而,高成本和缺乏熟練的專業人員是預測期內阻礙市場增長的因素之一。

可吸收組織間隔器的市場趨勢

在預測期內,可吸收組織間隔器的全球市場將由放射療法主導。

由於癌症患病率上升以及在治療各種癌症類型的放射治療期間越來越多地採用間隔物等因素,預計放射治療領域在預測期內將出現顯著的市場增長。 例如,BioMed Central Ltd 在 2022 年 4 月發表的一篇文章估計,到 2030 年,德國的新癌症病例數將增加 20%。 此外,根據美國癌症研究協會(AACR)2022年癌症進展報告,過去三年生活在美國的癌症倖存者人數有所增加,截至2022年1月1日已超過1800萬。到達

此外,在治療各種類型癌症的放療期間越來越多地採用間隔器也有助於這一領域的增長。 例如,根據 2022 年 7 月發表在《放射研究雜誌》上的一篇論文,間隔器在外照射放射治療 (EBRT) 和近距離放射治療中對前列腺放射治療的管理產生了有利影響。 根據 2021 年 10 月發表在《泌尿外科》雜誌上的一篇論文,臨床上越來越多地採用直腸間隔器來對抗輻射毒性。 間隔材料在患者的放射治療期間(約 3 個月)保持完好,之後被身體吸收並隨尿液排出。

可吸收組織間隔器市場-IMG1

北美主導可吸收組織間隔器市場,預計在預測期內也會如此

由於癌症發病率和患病率的增加以及癌症治療技術的進步等因素,預計北美的可吸收組織間隔器市場將出現顯著增長。 例如,根據美國癌症協會的最新消息,2023 年 1 月,美國估計報告了 288,300 例前列腺癌新病例和 52,550 例結直腸癌新病例。

此外,使用可注射直腸間隔器將直腸前表面與前列腺分開是減少直腸意外輻射劑量的潛在策略。 例如,根據 MDPI 於 2022 年 10 月發表的一篇文章,在美國,水凝膠間隔物在前列腺癌治療方案中越來越受歡迎。 在 SpaceOAR 獲得 FDA 批准後,越來越多的專家收到了水凝膠放置的轉介。 這種癌症治療的進步預計將在預測期內推動市場增長。

可吸收組織間隔器市場-IMG2

可吸收組織間隔器行業概覽

由於在全球和區域運營的公司數量不多,吸收性紙巾墊片市場具有整合性。 競爭格局包括具有市場份額的知名國際公司,例如 Biocomposites、Boston Scientific (Augmenix, Inc)、Bioprotect Ltd.、Palette Life Sciences, Inc、Becton、Dickinson, and Company (CR Bard),以及本地公司還對幾家公司進行了分析。

其他福利:

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 調查假設和市場定義
  • 本次調查的範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 癌症患病率增加
    • Tissue Spacer 的優勢
  • 市場製約因素
    • 成本高且缺乏熟練的專業人員
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分(市場規模(百萬美元))

  • 按產品類型
    • 水凝膠基底墊片
    • 可生物降解的氣球墊片
  • 通過使用
    • 放射治療
    • 傳染病控制
  • 最終用戶
    • 醫院
    • 門診手術中心
    • 其他最終用戶
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Biocomposites
    • Bioprotect Ltd.
    • Boston Scientific
    • Becton, Dickinson and Company(CR Bard)
    • Palette Life Sciences

第七章市場機會與未來趨勢

簡介目錄
Product Code: 69927

The absorbable tissue spacer market studied is anticipated to grow with a CAGR of 4.9%, during the forecast period.

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. Due to the fragility and immunosuppression, oncologic patients were reported to be at higher risk of COVID-19 complications and deaths. Hence, government initiatives were taken to overcome the complications. For instance, according to an article published by SAGE Publications, in December 2021, during the COVID-19 pandemic, the Regional Health Council converted selected hospitals for cancer care in oncologic hubs to create COVID-19-free zones and guarantee the continuation of cancer treatments safely. The European Institute of Oncology (IEO) IRCSS (Milan, Italy) was one of those. Therefore, even though the COVID-19 pandemic significantly impacted market growth in the initial phases, cancer treatments resumed following government initiatives, which significantly impacted the absorbable tissue spacer market. Additionally, as the COVID-19 cases started to decline, the market has returned to the normal levels of demand for radiotherapy and is anticipated to show significant growth over the forecast period.

Certain factors that are driving the market growth include the increasing prevalence of cancer and the advantages associated with tissue spacers. The growing number of people suffering from various cancers is the key driving factor for the growth of the market. For instance, as per the data published by the American Cancer Society in January 2023, around 1,958,310 people are expected to be diagnosed with new cancer cases in the United States in 2023. Thus, the increasing prevalence of cancer is likely to create a great demand for diagnosis and treatment. Additionally, according to a January 2023 update by the Australian Government, an estimated 20,640 new cases of breast cancer were diagnosed in 2022. Thus, the huge burden of cancers among the population is expected to increase the demand for absorbable tissue spacers to provide adequate protection and to produce a strong protective barrier during radiotherapy, thereby boosting the market growth.

Various initiatives taken by the key market players, such as product launches, expansion, and partnerships, are expected to boost the market's growth during the forecast period. For instance, in February 2022, Palette Life Sciences, commercialized Palette's portfolio of medical products. It expanded its Japanese offering, actively pursuing regulatory clearance for its Barrigel and Solesta brands. Such developments are expected to drive the growth of the market over the forecast period.

However, the high cost and lack of skilled professionals are some of the factors that are impeding the market growth over the forecast period.

Absorbable Tissue Spacer Market Trends

The Radiotherapy Segment to Hold Significant Share in the Global Absorbable Tissue Spacer Market Over the Forecast Period

The radiotherapy segment is expected to witness significant market growth over the forecast period owing to the factors such as the rising prevalence of cancer and the rising adoption of spacers during radiotherapy in treating various cancer types. For instance, according to an article published by BioMed Central Ltd in April 2022, the number of new cancer cases is estimated to increase by 20% by 2030 in Germany. Additionally, according to the American Association for Cancer Research (AACR) Cancer Progress Report 2022, in the past three years, there has been an increase in the number of cancer survivors living in the United States, reaching greater than 18 million as of January 1, 2022.

Additionally, the rising adoption of spacers during radiotherapy in treating various cancer types contributes to the segment's growth. For instance, according to an article published by the Journal of Radiation Research in July 2022, spacers had a favorable efficacy in the management of prostate radiotherapy in both external beam radiation therapy (EBRT) and brachytherapy. Also, according to an article published by Urology in October 2021, rectal spacers are being increasingly adopted into clinical practice to address radiation toxicity. The spacer material remains intact during the patient's radiation therapy (approximately 3 months), after which it is absorbed into the body and cleared in the urine.

Absorbable Tissue Spacer Market - IMG1

North America Dominates the Absorbable Tissue Spacer Market and Expects to do the Same Over the Forecast Period

North America is expected to show significant growth in the absorbable tissue spacer market owing to factors such as the increasing incidence and prevalence of cancers and progressing technological advancements in cancer treatment. For instance, according to the American Cancer Society update, in January 2023, an estimated 288,300 new prostate cancer cases and 52,550 new colon and rectum cases were reported in the United States.

In addition, the use of injectable rectal spacers to distance the anterior rectum from the prostate is a potential strategy to reduce the dose of unintended radiation to the rectum. For instance, according to an article published by MDPI, in October 2022, hydrogel spacers are gaining increasing popularity in the treatment regimen for prostate cancer in the United States. After the FDA approval of SpaceOAR, specialists received more referrals for hydrogel placements. Such advancement in cancer treatment is expected to drive the growth of the market over the forecast period.

Absorbable Tissue Spacer Market - IMG2

Absorbable Tissue Spacer Industry Overview

The absorbable tissue spacer market is consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well-known, including Biocomposites, Boston Scientific (Augmenix, Inc), Bioprotect Ltd., Palette Life Sciences, Inc., and Becton, Dickinson, and Company (CR Bard), among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cancer
    • 4.2.2 Advantages associated with Tissue Spacer
  • 4.3 Market Restraints
    • 4.3.1 High Cost and Lack of Skilled Professionals
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value in USD million)

  • 5.1 By Product Type
    • 5.1.1 Hydrogel Based Spacers
    • 5.1.2 Biodegradable Balloon Spacers
  • 5.2 By Application
    • 5.2.1 Radiotherapy
    • 5.2.2 Infection Management
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Ambulatory Surgical Centers
    • 5.3.3 Other End-Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Biocomposites
    • 6.1.2 Bioprotect Ltd.
    • 6.1.3 Boston Scientific
    • 6.1.4 Becton, Dickinson and Company (CR Bard)
    • 6.1.5 Palette Life Sciences

7 MARKET OPPORTUNITIES AND FUTURE TRENDS